Identifizierung und Charakterisierung einer alternativ gespleißten mRNA der Interleukin-4 Rezeptor alpha-Kette und Untersuchung der biologischen Funktion der verkürzten RezeptorvarianteAnja Möricke1131.114151.21.2.1161.2.217181.2.319201.31.3.11.3.1.121600#931.3.1.2221.3.1.3231.3.1.4241.3.1.51.3.2251.3.2.126271.3.2.22829230313323.13.1.13.1.23.2333.2.13.2.2343.2.3306#109308#11035151#923.2.43.2.53.2.6363.2.73.2.83.2.93.2.9.13.2.9.23.2.9.3373.2.103.2.113.2.123.2.133.2.143.2.1538393.33.43.4.13.4.23.4.33.4.440413.4.4.1423.4.4.23.4.53.4.63.4.6.1433.4.6.23.4.73.4.8443.4.9453.4.103.4.10.1435#1443.4.10.2463.4.10.33.4.10.43.5473.5.13.5.23.5.33.5.448269#473.5.53.5.5.13.5.5.2493.5.63.5.6.13.5.6.2503.63.6.13.6.1.1513.6.1.2523.6.23.6.3533.6.43.6.53.6.6543.73.83.9553.9.13.9.23.9.33.10563.1157424#3543.11.1583.11.2593.11.34604.1576#198616263608#17264627#414654.266485#31467573#24468497#19569383#230704.3424#22071724.473744.575550#5164.6764.6.14.6.277525#370784.6.3798081543#2694.6.4828384392#2815855.15.1.18687885.1.25.28990915.3925.493945.55.5.1955.5.2969798995.5.36100101 7 Abkürzungen102 8 Referenzen103104105106107108109110111112113114115 Anhang116117118 Lebenslauf119 Danksagung120 Erklärung an Eides Statt121deInhaltsverzeichnisHilfe 8 Referenzen [1] Howard, A.; Farrar, J.; Hilfiker, M.; Johnson, B.; Takatsu, K.; Hamaoka, T. und Paul, W. E. (1982): Identification of a T cell-derived B cell growth factor distinct from interleukin 2., J Exp Med, (Band 155), Seite 914-924. [2] Yokota, T.; Otsuka, T.; Mosmann, T.; Banchereau, J.; DeFrance, T.; Blanchard, D.; De Vries, J. E.; Lee, F. und Arai, K. (1986): Isolation and characterization of a human interleukin cDNA clone, homologous to mouse B-cell stimulatory factor 1, that expresses B-cell- and T-cell-stimulating activities, Proc Natl Acad Sci U S A, (Band 83), No. 16, Seite 5894-8. [3] Mitchell, L. C.; Davis, L. S. und Lipsky, P. E. (1989): Promotion of human T lymphocyte proliferation by IL-4, J Immunol, (Band 142), No. 5, Seite 1548-57. [4] Toi, M.; Harris, A. L. und Bicknell, R. (1991): Interleukin-4 is a potent mitogen for capillary endothelium, Biochem Biophys Res Commun, (Band 174), No. 3, Seite 1287-93. [5] Feghali, C. A.; Bost, K. L.; Boulware, D. W. und Levy, L. S. (1992): Human recombinant interleukin-4 induces proliferation and interleukin-6 production by cultured human skin fibroblasts, Clin Immunol Immunopathol, (Band 63), No. 2, Seite 182-7. [6] Snapper, C. M.; Finkelman, F. D. und Paul, W. E. (1988): Regulation of IgG1 and IgE production by interleukin 4, Immunol Rev, (Band 102), Seite 51-75. [7] Coffman, R. L.; Lebman, D. A. und Rothman, P. (1993): Mechanism and regulation of immunoglobulin isotype switching, Adv Immunol, (Band 54), Seite 229-70. [8] Kuhn, R.; Rajewsky, K. und Muller, W. (1991): Generation and analysis of interleukin-4 deficient mice, Science, (Band 254), No. 5032, Seite 707-10. [9] Conrad, D. H.; Keegan, A. D.; Kalli, K. R.; Van Dusen, R.; Rao, M. und Levine, A. D. (1988): Superinduction of low affinity IgE receptors on murine B lymphocytes by lipopolysaccharide and IL-4, J Immunol, (Band 141), No. 4, Seite 1091-7. [10] Defrance, T.; Aubry, J. P.; Rousset, F.; Vanbervliet, B.; Bonnefoy, J. Y.; Arai, N.; Takebe, Y.; Yokota, T.; Lee, F.; Arai, K. und et al. (1987): Human recombinant interleukin 4 induces Fc epsilon receptors (CD23) on normal human B lymphocytes, J Exp Med, (Band 165), No. 6, Seite 1459-67. [11] Noelle, R.; Krammer, P. H.; Ohara, J.; Uhr, J. W. und Vitetta, E. S. (1984): Increased expression of Ia antigens on resting B cells: an additional role for B-cell growth factor, Proc Natl Acad Sci U S A, (Band 81), No. 19, Seite 6149-53. [12] Rousset, F.; Malefijt, R. W.; Slierendregt, B.; Aubry, J. P.; Bonnefoy, J. Y.; Defrance, T.; Banchereau, J. und de Vries, J. E. (1988): Regulation of Fc receptor for IgE (CD23) and class II MHC antigen expression on Burkitt's lymphoma cell lines by human IL-4 and IFN-gamma, J Immunol, (Band 140), No. 8, Seite 2625-32.

[13] Shields, J. G.; Armitage, R. J.; Jamieson, B. N.; Beverley, P. C. und Callard, R. E. (1989): Increased expression of surface IgM but not IgD or IgG on human B cells in response to IL-4, Immunology, (Band 66), No. 2, Seite 224-7. [14] Maggi, E.; Parronchi, P.; Manetti, R.; Simonelli, C.; Piccinni, M. P.; Rugiu, F. S.; De Carli, M.; Ricci, M. und Romagnani, S. (1992): Reciprocal regulatory effects of IFN-gamma and IL-4 on the in vitro development of human Th1 and Th2 clones, J Immunol, (Band 148), No. 7, Seite 2142-7. [15] Scott, P. (1991): IFN-gamma modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis, J Immunol, (Band 147), No. 9, Seite 3149-55. [16] Seder, R. A.; Boulay, J. L.; Finkelman, F.; Barbier, S.; Ben Sasson, S. Z.; Le Gros, G. und Paul, W. E. (1992): CD8+ T cells can be primed in vitro to produce IL-4, J Immunol, (Band 148), No. 6, Seite 1652-6. [17] Mosmann, T. R.; Cherwinski, H.; Bond, M. W.; Giedlin, M. A. und Coffman, R. L. (1986): Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins, J Immunol, (Band 136), No. 7, Seite 2348-57. [18] Romagnani, S. (1994): Lymphokine production by human T cells in disease states, Annu Rev Immunol, (Band 12), Seite 227-57. [19] Mosmann, T. R. und Sad, S. (1996): The expanding universe of T-cell subsets: Th1, Th2 and more, Immunol Today, (Band 17), No. 3, Seite 138-46. [20] Song, Z.; Casolaro, V.; Chen, R.; Georas, S. N.; Monos, D. und Ono, S. J. (1996): Polymorphic nucleotides within the human IL-4 promoter that mediate overexpression of the gene, J Immunol, (Band 156), No. 2, Seite 424-9. [21] Hershey, G. K.; Friedrich, M. F.; Esswein, L. A.; Thomas, M. L. und Chatila, T. A. (1997): The association of atopy with a gain-of-function mutation in the alpha subunit of the interleukin-4 receptor, N Engl J Med, (Band 337), No. 24, Seite 1720-5. [22] Mitsuyasu, H.; Izuhara, K.; Mao, X. Q.; Gao, P. S.; Arinobu, Y.; Enomoto, T.; Kawai, M.; Sasaki, S.; Dake, Y.; Hamasaki, N.; Shirakawa, T. und Hopkin, J. M. (1998): Ile50Val variant of IL4R alpha upregulates IgE synthesis and associates with atopic asthma, Nat Genet, (Band 19), No. 2, Seite 119-20. [23] Akashi, K. (1993): The role of interleukin-4 in the negative regulation of leukemia cell growth, Leuk Lymphoma, (Band 9), No. 3, Seite 205-9. [24] Okabe, M.; Kuni eda, Y.; Sugiwura, T.; Tanaka, M.; Miyagishima, T.; Saiki, I.; Minagawa, T.; Kurosawa, M.; Itaya, T. und Miyazaki, T. (1991): Inhibitory effect of interleukin-4 on the in vitro growth of Ph1-positive acute lymphoblastic leukemia cells, Blood, (Band 78), No. 6, Seite 1574-80.

[25] Akashi, K.; Shibuya, T.; Harada, M.; Takamatsu, Y.; Uike, N.; Eto, T. und Niho, Y. (1991): Interleukin 4 suppresses the spontaneous growth of chronic myelomonocytic leukemia cells, J Clin Invest, (Band 88), No. 1, Seite 223-30. [26] Yanagisawa, K.; Hatta, N.; Watanabe, I.; Horiuchi, T.; Hasegawa, H. und Fujita, S. (1995): IL-4 stimulates the growth of chronic myelomonocytic leukemia cells (CMMoL) once leukemic transformation has occurred, Leukemia, (Band 9), No. 6, Seite 1056-9. [27] Jansen, J.H.; Fibbe, W.E.; Wientjens, G.J.; Willemze, R. und Kluin-Nelemans, J.C. (1993): Inhibitory effect of interleukin-4 on the proliferation of acute myeloid leukemia cells with myelo-monocytic differentiation (AML-M4/M5); the role of interleukin-6., Leukemia, (Band 7), No. 643. [28] Spits, H.; Yssel, H.; Takebe, Y.; Arai, N.; Yokota, T.; Lee, F.; Arai, K.; Banchereau, J. und de Vries, J. E. (1987): Recombinant interleukin 4 promotes the growth of human T cells, J Immunol, (Band 139), No. 4, Seite 1142-7. [29] Spits, H.; Yssel, H.; Paliard, X.; Kastelein, R.; Figdor, C. und de Vries, J. E. (1988): IL-4 inhibits IL-2-mediated induction of human lymphokine-activated killer cells, but not the generation of antigen-specific cytotoxic T lymphocytes in mixed leukocyte cultures, J Immunol, (Band 141), No. 1, Seite 29-36. [30] Nagler, A.; Lanier, L. L. und Phillips, J. H. (1988): The effects of IL-4 on human natural killer cells. A potent regulator of IL-2 activation and proliferation, J Immunol, (Band 141), No. 7, Seite 2349-51. [31] Kawakami, Y.; Custer, M. C.; Rosenberg, S. A. und Lotze, M. T. (1989): IL-4 regulates IL-2 induction of lymphokine-activated killer activity from human lymphocytes, J Immunol, (Band 142), No. 10, Seite 3452-61. [32] Widmer, M. B.; Acres, R. B.; Sassenfeld, H. M. und Grabstein, K. H. (1987): Regulation of cytolytic cell populations from human peripheral blood by B cell stimulatory factor 1 (interleukin 4), J Exp Med, (Band 166), No. 5, Seite 1447-55. [33] Kawakami, Y.; Rosenberg, S. A. und Lotze, M. T. (1988): Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma, J Exp Med, (Band 168), No. 6, Seite 2183-91. [34] Fanslow, W. C.; Clifford, K.; VandenBos, T.; Teel, A.; Armitage, R. J. und Beckmann, M. P. (1990): A soluble form of the interleukin 4 receptor in biological fluids, Cytokine, (Band 2), No. 6, Seite 398-401. [35] Golumbek, P. T.; Lazenby, A. J.; Levitsky, H. I.; Jaffee, L. M.; Karasuyama, H.; Baker, M. und Pardoll, D. M. (1991): Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4, Science, (Band 254), No. 5032, Seite 713-6.

[36] Grusby, M. J.; Nabavi, N.; Wong, H.; Dick, R. F.; Bluestone, J. A.; Schotz, M. C. und Glimcher, L. H. (1990): Cloning of an interleukin-4 inducible gene from cytotoxic T lymphocytes and its identification as a lipase, Cell, (Band 60), No. 3, Seite 451-9. [37] Russell, S. M.; Keegan, A. D.; Harada, N.; Nakamura, Y.; Noguchi, M.; Leland, P.; Friedmann, M. C.; Miyajima, A.; Puri, R. K. und Paul, W. E. (1993): Interleukin-2 receptor gamma chain: a functional component of the interleukin-4 receptor, Science, (Band 262), No. 5141, Seite 1880-3. [38] Kondo, M.; Takeshita, T.; Ishii, N.; Nakamura, M.; Watanabe, S.; Arai, K. und Sugamura, K. (1993): Sharing of the interleukin-2 (IL-2) receptor gamma chain between receptors for IL-2 and IL-4, Science, (Band 262), No. 5141, Seite 1874-7. [39] Aman, M. J.; Tayebi, N.; Obiri, N. I.; Puri, R. K.; Modi, W. S. und Leonard, W. J. (1996): cDNA cloning and characterization of the human interleukin 13 receptor alpha chain, J Biol Chem, (Band 271), No. 46, Seite 29265-29270. [40] Miloux, B.; Laurent, P.; Bonnin, O.; Lupker, J.; Caput, D.; Vita, N. und Ferrara, P. (1997): Cloning of the human IL-13R alpha1 chain and reconstitution with the IL4R alpha of a functional IL-4/IL-13 receptor complex, FEBS Lett, (Band 401), No. 2-3, Seite 163-6. [41] Caput, D.; Laurent, P.; Kaghad, M.; Lelias, J. M.; Lefort, S.; Vita, N. und Ferrara, P. (1996): Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor alpha chain, J Biol Chem, (Band 271), No. 28, Seite 16921-6. [42] Park, L. S.; Friend, D.; Sassenfeld, H. M. und Urdal, D. L. (1987): Characterization of the human B cell stimulatory factor 1 receptor, J Exp Med, (Band 166), No. 2, Seite 476-88. [43] Bazan, J. F. (1990): Structural design and molecular evolution of a cytokine receptor superfamily, Proc Natl Acad Sci U S A, (Band 87), No. 18, Seite 6934-8. [44] Miyazaki, T.; Maruyama, M.; Yamada, G.; Hatakeyama, M. und Taniguchi, T. (1991): The integrity of the conserved 'WS motif' common to IL-2 and other cytokine receptors is essential for ligand binding and signal transduction, Embo J, (Band 10), No. 11, Seite 3191-7. [45] Yin, T.; Tsang, M. L. und Yang, Y. C. (1994): JAK1 kinase forms complexes with interleukin-4 receptor and 4PS/insulin receptor substrate-1-like protein and is activated by interleukin-4 and interleukin-9 in T lymphocytes, J Biol Chem, (Band 269), No. 43, Seite 26614-7. [46] Miyazaki, T.; Kawahara, A.; Fujii, H.; Nakagawa, Y.; Minami, Y.; Liu, Z. J.; Oishi, I.; Silvennoinen, O.; Witthuhn, B. A.; Ihle, J. N. und et al. (1994): Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits, Science, (Band 266), No. 5187, Seite 1045-7.

[47] Ihle, J. N. und Kerr, I. M. (1995): Jaks and Stats in signaling by the cytokine receptor superfamily, Trends Genet, (Band 11), No. 2, Seite 69-74. [48] Keegan, A. D.; Nelms, K.; White, M.; Wang, L. M.; Pierce, J. H. und Paul, W. E. (1994): An IL-4 receptor region containing an insulin receptor motif is important for IL-4-mediated IRS-1 phosphorylation and cell growth, Cell, (Band 76), No. 5, Seite 811-20. [49] Sun, X. J.; Wang, L. M.; Zhang, Y.; Yenush, L.; Myers, M. G., Jr.; Glasheen, E.; Lane, W. S.; Pierce, J. H. und White, M. F. (1995): Role of IRS-2 in insulin and cytokine signalling, Nature, (Band 377), No. 6545, Seite 173-7. [50] O'Neill, TJ; Craparo, A. und Gustafson, T. A. (1994): Characterization of an interaction between insulin receptor substrate 1 and the insulin receptor by using the two-hybrid system, Mol Cell Biol, (Band 14), No. 10, Seite 6433-42. [51] Wang, L. M.; Myers, M. G., Jr.; Sun, X. J.; Aaronson, S. A.; White, M. und Pierce, J. H. (1993): IRS-1: essential for insulin- and IL-4-stimulated mitogenesis in hematopoietic cells, Science, (Band 261), No. 5128, Seite 1591-4. [52] Hou, J.; Schindler, U.; Henzel, W. J.; Ho, T. C.; Brasseur, M. und McKnight, S. L. (1994): An interleukin-4-induced transcription factor: IL-4 Stat, Science, (Band 265), No. 5179, Seite 1701-6. [53] Kotanides, H. und Reich, N. C. (1993): Requirement of tyrosine phosphorylation for rapid activation of a DNA binding factor by IL-4, Science, (Band 262), No. 5137, Seite 1265-7. [54] Kotanides, H. und Reich, N. C. (1996): Interleukin-4-induced STAT6 recognizes and activates a target site in the promoter of the interleukin-4 receptor gene, J Biol Chem, (Band 271), No. 41, Seite 25555-61. [55] Schindler, C.; Kashleva, H.; Pernis, A.; Pine, R. und Rothman, P. (1994): STF-IL-4: a novel IL-4-induced signal transducing factor, Embo J, (Band 13), No. 6, Seite 1350-6. [56] Takeda, K.; Tanaka, T.; Shi, W.; Matsumoto, M.; Minami, M.; Kashiwamura, S.; Nakanishi, K.; Yoshida, N.; Kishimoto, T. und Akira, S. (1996): Essential role of Stat6 in IL-4 signalling, Nature, (Band 380), No. 6575, Seite 627-30. [57] Ryan, J. J.; McReynolds, L. J.; Keegan, A.; Wang, L. H.; Garfein, E.; Rothman, P.; Nelms, K. und Paul, W. E. (1996): Growth and gene expression are predominantly controlled by distinct regions of the human IL-4 receptor, Immunity, (Band 4), No. 2, Seite 123-32.

[58] Deutsch, H. H.; Koettnitz, K.; Chung, J. und Kalthoff, F. S. (1995): Distinct sequence motifs within the cytoplasmic domain of the human IL-4 receptor differentially regulate apoptosis inhibition and cell growth, J Immunol, (Band 154), No. 8, Seite 3696-703. [59] Pernis, A.; Witthuhn, B.; Keegan, A. D.; Nelms, K.; Garfein, E.; Ihle, J. N.; Paul, W. E.; Pierce, J. H. und Rothman, P. (1995): Interleukin 4 signals through two related pathways, Proc Natl Acad Sci U S A, (Band 92), No. 17, Seite 7971-5. [60] Zamorano, J. und Keegan, A. D. (1998): Regulation of apoptosis by tyrosine-containing domains of IL-4R alpha: Y497 and Y713, but not the STAT6-docking tyrosines, signal protection from apoptosis, J Immunol, (Band 161), No. 2, Seite 859-67. [61] Harada, N.; Yang, G.; Miyajima, A. und Howard, M. (1992): Identification of an essential region for growth signal transduction in the cytoplasmic domain of the human interleukin-4 receptor, J Biol Chem, (Band 267), No. 32, Seite 22752-8. [62] Seldin, D. C. und Leder, P. (1994): Mutational analysis of a critical signaling domain of the human interleukin 4 receptor, Proc Natl Acad Sci U S A, (Band 91), No. 6, Seite 2140-4. [63] Harada, N.; Higuchi, K.; Wakao, H.; Hamasaki, N. und Izuhara, K. (1998): Identification of the critical portions of the human IL-4 receptor alpha chain for activation of STAT6, Biochem Biophys Res Commun, (Band 246), No. 3, Seite 675-80. [64] Mikita, T.; Campbell, D.; Wu, P. G.; Williamson, K. und Schindler, U. (1996): Requirements for interleukin-4-induced gene expression and functional characterization of Stat6, Mol Cell Biol, (Band 16), No. 10, Seite 5811-20. [65] Moriggl, R.; Erhardt, I.; Kammer, W.; Berchtold, S.; Schnarr, B.; Lischke, A.; Groner, B. und Friedrich, K. (1998): Activation of STAT6 is not dependent on phosphotyrosine-mediated docking to the interleukin-4 receptor and can be blocked by dominant-negative mutants of both receptor subunits, Eur J Biochem, (Band 251), No. 1-2, Seite 25-35. [66] Lewis, B. (1996): Nuclear splicing, Lewis, B., Genes, Seite 885-920. [67] Zahler, A. M.; Lane, W. S.; Stolk, J. A. und Roth, M. B. (1992): SR proteins: a conserved family of pre-mRNA splicing factors, Genes Dev, (Band 6), No. 5, Seite 837-47. [68] Cavaloc, Y.; Popielarz, M.; Fuchs, J. P.; Gattoni, R. und Stevenin, J. (1994): Characterization and cloning of the human splicing factor 9G8: a novel 35 kDa factor of the serine/arginine protein family, Embo J, (Band 13), No. 11, Seite 2639-49. [69] Screaton, G. R.; Caceres, J. F.; Mayeda, A.; Bell, M. V.; Plebanski, M.; Jackson, D. G.; Bell, J. I. und Krainer, A. R. (1995): Identification and characterization of three members of the human SR family of pre-mRNA splicing factors, Embo J, (Band 14), No. 17, Seite 4336-49.

[70] Chaudhary, N.; McMahon, C. und Blobel, G. (1991): Primary structure of a human arginine-rich nuclear protein that colocalizes with spliceosome components, Proc Natl Acad Sci U S A, (Band 88), No. 18, Seite 8189-93. [71] Ge, H.; Zuo, P. und Manley, J. L. (1991): Primary structure of the human splicing factor ASF reveals similarities with Drosophila regulators, Cell, (Band 66), No. 2, Seite 373-82. [72] Fu, X. D. und Maniatis, T. (1992): Isolation of a complementary DNA that encodes the mammalian splicing factor SC35, Science, (Band 256), No. 5056, Seite 535-8. [73] Krainer, A. R.; Conway, G. C. und Kozak, D. (1990): Purification and characterization of pre-mRNA splicing factor SF2 from HeLa cells, Genes Dev, (Band 4), No. 7, Seite 1158-71. [74] Fu, X. D. (1995): The superfamily of arginine/serine-rich splicing factors, RNA, (Band 1), No. 7, Seite 663-80. [75] Valcarcel, J.; Gaur, R. K.; Singh, R. und Green, M. R. (1996): Interaction of U2AF65 RS region with pre-mRNA branch point and promotion of base pairing with U2 snRNA [corrected] [published erratum appears in Science 1996 Oct 4;274(5284):21], Science, (Band 273), No. 5282, Seite 1706-9. [76] Zamore, P. D.; Patton, J. G. und Green, M. R. (1992): Cloning and domain structure of the mammalian splicing factor U2AF, Nature, (Band 355), No. 6361, Seite 609-14. [77] Newman, A. J. (1997): The role of U5 snRNP in pre-mRNA splicing, Embo J, (Band 16), No. 19, Seite 5797-800. [78] Staknis, D. und Reed, R. (1994): SR proteins promote the first specific recognition of Pre-mRNA and are present together with the U1 small nuclear ribonucleoprotein particle in a general splicing enhancer complex, Mol Cell Biol, (Band 14), No. 11, Seite 7670-82. [79] Kohtz, J. D.; Jamison, S. F.; Will, C. L.; Zuo, P.; Luhrmann, R.; Garcia Blanco, M. A. und Manley, J. L. (1994): Protein-protein interactions and 5'-splice-site recognition in mammalian mRNA precursors, Nature, (Band 368), No. 6467, Seite 119-24. [80] Wu, J. Y. und Maniatis, T. (1993): Specific interactions between proteins implicated in splice site selection and regulated alternative splicing, Cell, (Band 75), No. 6, Seite 1061-70. [81] Zuo, P. und Maniatis, T. (1996): The splicing factor U2AF35 mediates critical protein-protein interactions in constitutive and enhancer-dependent splicing, Genes Dev, (Band 10), No. 11, Seite 1356-68.

[82] Champion-Arnaud, P. und Reed, R. (1994): The prespliceosome components SAP 49 and SAP 145 interact in a complex implicated in tethering U2 snRNP to the branch site, Genes Dev, (Band 8), No. 16, Seite 1974-83. [83] Gozani, O.; Feld, R. und Reed, R. (1996): Evidence that sequence-independent binding of highly conserved U2 snRNP proteins upstream of the branch site is required for assembly of spliceosomal complex A, Genes Dev, (Band 10), No. 2, Seite 233-43. [84] Madhani, H. D. und Guthrie, C. (1992): A novel base-pairing interaction between U2 and U6 snRNAs suggests a mechanism for the catalytic activation of the spliceosome, Cell, (Band 71), No. 5, Seite 803-17. [85] Manley, J. L. und Tacke, R. (1996): SR proteins and splicing control, Genes Dev, (Band 10), No. 13, Seite 1569-79. [86] Krainer, A. R.; Conway, G. C. und Kozak, D. (1990): The essential pre-mRNA splicing factor SF2 influences 5' splice site selection by activating proximal sites, Cell, (Band 62), No. 1, Seite 35-42. [87] Caceres, J. F.; Stamm, S.; Helfman, D. M. und Krainer, A. R. (1994): Regulation of alternative splicing in vivo by overexpression of antagonistic splicing factors, Science, (Band 265), No. 5179, Seite 1706-9. [88] Adams, M. D.; Rudner, D. Z. und Rio, D. C. (1996): Biochemistry and regulation of pre-mRNA splicing, Curr Opin Cell Biol, (Band 8), No. 3, Seite 331-9. [89] Tanaka, K.; Watakabe, A. und Shimura, Y. (1994): Polypurine sequences within a downstream exon function as a splicing enhancer, Mol Cell Biol, (Band 14), No. 2, Seite 1347-54. [90] Wang, Z.; Hoffmann, H. M. und Grabowski, P. J. (1995): Intrinsic U2AF binding is modulated by exon enhancer signals in parallel with changes in splicing activity, RNA, (Band 1), No. 1, Seite 21-35. [91] Lavigueur, A.; La Branche, H.; Kornblihtt, A. R. und Chabot, B. (1993): A splicing enhancer in the human fibronectin alternate ED1 exon interacts with SR proteins and stimulates U2 snRNP binding, Genes Dev, (Band 7), No. 12A, Seite 2405-17. [92] Watakabe, A.; Tanaka, K. und Shimura, Y. (1993): The role of exon sequences in splice site selection, Genes Dev, (Band 7), No. 3, Seite 407-18. [93] Sun, Q.; Mayeda, A.; Hampson, R. K.; Krainer, A. R. und Rottman, F. M. (1993): General splicing factor SF2/ASF promotes alternative splicing by binding to an exonic splicing enhancer, Genes Dev, (Band 7), No. 12B, Seite 2598-608. [94] Woppmann, A.; Will, C. L.; Kornstadt, U.; Zuo, P.; Manley, J. L. und Luhrmann, R. (1993): Identification of an snRNP-associated kinase activity that phosphorylates arginine/serine rich domains typical of splicing factors, Nucleic Acids Res, (Band 21), No. 12, Seite 2815-22.

[95] Mermoud, J. E.; Cohen, P. T. und Lamond, A. I. (1994): Regulation of mammalian spliceosome assembly by a protein phosphorylation mechanism, Embo J, (Band 13), No. 23, Seite 5679-88. [96] Mermoud, J. E.; Cohen, P. und Lamond, A. I. (1992): Ser/Thr-specific protein phosphatases are required for both catalytic steps of pre-mRNA splicing, Nucleic Acids Res, (Band 20), No. 20, Seite 5263-9. [97] Gui, J. F.; Lane, W. S. und Fu, X. D. (1994): A serine kinase regulates intracellular localization of splicing factors in the cell cycle, Nature, (Band 369), No. 6482, Seite 678-82. [98] Gui, J. F.; Tronchere, H.; Chandler, S. D. und Fu, X. D. (1994): Purification and characterization of a kinase specific for the serine- and arginine-rich pre-mRNA splicing factors, Proc Natl Acad Sci U S A, (Band 91), No. 23, Seite 10824-8. [99] Wang, H. Y.; Lin, W.; Dyck, J. A.; Yeakley, J. M.; Songyang, Z.; Cantley, L. C. und Fu, X. D. (1998): SRPK2: a differentially expressed SR protein-specific kinase involved in mediating the interaction and localization of pre-mRNA splicing factors in mammalian cells, J Cell Biol, (Band 140), No. 4, Seite 737-50. [100] Colwill, K.; Feng, L. L.; Yeakley, J. M.; Gish, G. D.; Caceres, J. F.; Pawson, T. und Fu, X. D. (1996): SRPK1 and Clk/Sty protein kinases show distinct substrate specificities for serine/arginine-rich splicing factors, J Biol Chem, (Band 271), No. 40, Seite 24569-75. [101] Melcher, M. L. und Thorner, J. (1996): Identification and characterization of the CLK1 gene product, a novel CaM kinase-like protein kinase from the yeast Saccharomyces cerevisiae, J Biol Chem, (Band 271), No. 47, Seite 29958-68. [102] Eperon, I. C.; Ireland, D. C.; Smith, R. A.; Mayeda, A. und Krainer, A. R. (1993): Pathways for selection of 5' splice sites by U1 snRNPs and SF2/ASF, Embo J, (Band 12), No. 9, Seite 3607-17. [103] Zahler, A. M.; Neugebauer, K. M.; Lane, W. S. und Roth, M. B. (1993): Distinct functions of SR proteins in alternative pre-mRNA splicing, Science, (Band 260), No. 5105, Seite 219-22. [104] Zahler, A. M. und Roth, M. B. (1995): Distinct functions of SR proteins in recruitment of U1 small nuclear ribonucleoprotein to alternative 5' splice sites, Proc Natl Acad Sci U S A, (Band 92), No. 7, Seite 2642-6. [105] Lin, C. H. und Patton, J. G. (1995): Regulation of alternative 3' splice site selection by constitutive splicing factors, RNA, (Band 1), No. 3, Seite 234-45.

[106] Utz, P. J.; Hottelet, M.; van Venrooij, W. J. und Anderson, P. (1998): Association of phosphorylated serine/arginine (SR) splicing factors with the U1-small ribonucleoprotein (snRNP) autoantigen complex accompanies apoptotic cell death, J Exp Med, (Band 187), No. 4, Seite 547-60. [107] Smith, C. W.; Patton, J. G. und Nadal Ginard, B. (1989): Alternative splicing in the control of gene expression, Annu Rev Genet, (Band 23), Seite 527-77. [108] Raines, M. A.; Liu, L.; Quan, S. G.; Joe, V.; DiPersio, J. F. und Golde, D. W. (1991): Identification and molecular cloning of a soluble human granulocyte-macrophage colony-stimulating factor receptor, Proc-Natl-Acad-Sci-U-S-A, (Band 88), No. 18, Seite 8203-7. [109] Pleiman, C. M.; Gimpel, S. D.; Park, L. S.; Harada, H.; Taniguchi, T. und Ziegler, S. F. (1991): Organization of the murine and human interleukin-7 receptor genes: two mRNAs generated by differential splicing and presence of a type I-interferon-inducible promoter, Mol Cell Biol, (Band 11), No. 6, Seite 3052-9. [110] Horiuchi, S.; Koyanagi, Y.; Zhou, Y.; Miyamoto, H.; Tanaka, Y.; Waki, M.; Matsumoto, A.; Yamamoto, M. und Yamamoto, N. (1994): Soluble interleukin-6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism, Eur J Immunol, (Band 24), No. 8, Seite 1945-8. [111] Ross, R. J.; Esposito, N.; Shen, X. Y.; Von Laue, S.; Chew, S. L.; Dobson, P. R.; Postel Vinay, M. C. und Finidori, J. (1997): A short isoform of the human growth hormone receptor functions as a dominant negative inhibitor of the full-length receptor and generates large amounts of binding protein, Mol Endocrinol, (Band 11), No. 3, Seite 265-73. [112] Gale, R. E.; Freeburn, R. W.; Khwaja, A.; Chopra, R. und Linch, D. C. (1998): A truncated isoform of the human beta chain common to the receptors for granulocyte-macrophage colony-stimulating factor, interleukin-3 (IL-3), and IL-5 with increased mRNA expression in some patients with acute leukemia, Blood, (Band 91), No. 1, Seite 54-63. [113] Tuypens, T.; Plaetinck, G.; Baker, E.; Sutherland, G.; Brusselle, G.; Fiers, W.; Devos, R. und Tavernier, J. (1992): Organization and chromosomal localization of the human interleukin 5 receptor alpha-chain gene, Eur Cytokine Netw, (Band 3), No. 5, Seite 451-9. [114] Mosley, B.; Beckmann, M. P.; March, C. J.; Idzerda, R. L.; Gimpel, S. D.; VandenBos, T.; Friend, D.; Alpert, A.; Anderson, D. und Jackson, J. (1989): The murine interleukin-4 receptor: molecular cloning and characterization of secreted and membrane bound forms, Cell, (Band 59), No. 2, Seite 335-48.

[115] Nakamura, Y.; Komatsu, N. und Nakauchi, H. (1992): A truncated erythropoietin receptor that fails to prevent programmed cell death of erythroid cells, Science, (Band 257), No. 5073, Seite 1138-41. [116] Vandenbark, G. R.; deCastro, C. M.; Taylor, H.; Dew Knight, S. und Kaufman, R. E. (1992): Cloning and structural analysis of the human c-kit gene, Oncogene, (Band 7), No. 7, Seite 1259-66. [117] Wypych, J.; Bennett, L. G.; Schwartz, M. G.; Clogston, C. L.; Lu, H. S.; Broudy, V. C.; Bartley, T. D.; Parker, V. P. und Langley, K. E. (1995): Soluble kit receptor in human serum, Blood, (Band 85), No. 1, Seite 66-73. [118] Heaney, M. L. und Golde, D. W. (1996): Soluble cytokine receptors, Blood, (Band 87), No. 3, Seite 847-57. [119] Budel, L. M.; Dong, F.; Lowenberg, B. und Touw, I. P. (1995): Hematopoietic growth factor receptors: structure variations and alternatives of receptor complex formation in normal hematopoiesis and in hematopoietic disorders, Leukemia, (Band 9), No. 4, Seite 553-61. [120] Crosier, K. E.; Hall, L. R.; Vitas, M. R. und Crosier, P. S. (1997): Expression and functional analysis of two isoforms of the human GM-CSF receptor alpha chain in myeloid development and leukaemia, Br J Haematol, (Band 98), No. 3, Seite 540-8. [121] Heaney, M. L.; Vera, J. C.; Raines, M. A. und Golde, D. W. (1995): Membrane-associated and soluble granulocyte/macrophage-colony-stimulating factor receptor alpha subunits are independently regulated in HL-60 cells, Proc Natl Acad Sci U S A, (Band 92), No. 6, Seite 2365-9. [122] Idzerda, R. L.; March, C. J.; Mosley, B.; Lyman, S. D.; Vanden Bos, T.; Gimpel, S. D.; Din, W. S.; Grabstein, K. H.; Widmer, M. B. und Park, L. S. (1990): Human interleukin 4 receptor confers biological responsiveness and defines a novel receptor superfamily, J Exp Med, (Band 171), No. 3, Seite 861-73. [123] Platzer, C.; Ode Hakim, S.; Reinke, P.; Docke, W. D.; Ewert, R. und Volk, H. D. (1994): Quantitative PCR analysis of cytokine transcription patterns in peripheral mononuclear cells after anti-CD3 rejection therapy using two novel multispecific competitor fragments, Transplantation, (Band 58), No. 2, Seite 264-8. [124] Kebelmann-Betzing, C.; Seeger, K.; Dragon, S.; Schmitt, G.; Möricke, A.; Schild, T. A.; Henze, G. und Beyermann, B. (1998): Advantages of a new Taq DNA polymerase in multiplex PCR and time-release PCR, Biotechniques, (Band 24 (1)), Seite 154-158. [125] Wrighton, N.; Campbell, L. A.; Harada, N.; Miyajima, A. und Lee, F. (1992): The murine interleukin-4 receptor gene: genomic structure, expression and potential for alternative splicing, Growth Factors, (Band 6), No. 2, Seite 103-18.

[126] Enssle, K.; Enders, B.; Kurrle, R.; Lauffer, L.; Schorlemmer, H. U.; Dickneite, G.; Kanzy, E. J. und Seiler, F. R. (1995): Biology of natural and recombinant soluble interleukin-4 receptor, Behring Inst Mitt, (Band 96), Seite 103-17. [127] Malabarba, M. G.; Kirken, R. A.; Rui, H.; Koettnitz, K.; Kawamura, M.; JJ, O. Shea; Kalthoff, F. S. und Farrar, W. L. (1995): Activation of JAK3, but not JAK1, is critical to interleukin-4 (IL4) stimulated proliferation and requires a membrane-proximal region of IL4 receptor alpha, J Biol Chem, (Band 270), No. 16, Seite 9630-7. [128] Chen, C. Y.; Xu, N. und Shyu, A. B. (1995): mRNA decay mediated by two distinct Au-rich elements from c-fos and granulocyte-macrophage colony-stimulating factor transcripts: different deadenylation kinetics and uncoupling from translation, Mol Cell Biol, (Band 15), No. 10, Seite 5777-88. [129] Goldberg, M. A.; Gaut, C. C. und Bunn, H. F. (1991): Erythropoietin mRNA levels are governed by both the rate of gene transcription and posttranscriptional events, Blood, (Band 77), No. 2, Seite 271-7 *LHM: Bestand in der Charit‚ -> siehe Zeitschriftenkatalog!. [130] Seiser, C.; Posch, M.; Thompson, N. und Kuhn, L. C. (1995): Effect of transcription inhibitors on the iron-dependent degradation of transferrin receptor mRNA, J Biol Chem, (Band 270), No. 49, Seite 29400-6. [131] Rajagopalan, L. E. und Malter, J. S. (1997): Regulation of eukaryotic messenger RNA turnover, Prog Nucleic Acid Res Mol Biol, (Band 56), Seite 257-86. [132] Ross, J. (1996): Control of messenger RNA stability in higher eukaryotes, Trends Genet, (Band 12), No. 5, Seite 171-5. [133] Waterhouse, N.; Kumar, S.; Song, Q.; Strike, P.; Sparrow, L.; Dreyfuss, G.; Alnemri, E. S.; Litwack, G.; Lavin, M. und Watters, D. (1996): Heteronuclear ribonucleoproteins C1 and C2, components of the spliceosome, are specific targets of interleukin 1beta-converting enzyme-like proteases in apoptosis, J Biol Chem, (Band 271), No. 46, Seite 29335-41. [134] Casciola Rosen, L. A.; Miller, D. K.; Anhalt, G. J. und Rosen, A. (1994): Specific cleavage of the 70-kDa protein component of the U1 small nuclear ribonucleoprotein is a characteristic biochemical feature of apoptotic cell death, J Biol Chem, (Band 269), No. 49, Seite 30757-60. [135] Boise, L. H. und Thompson, C. B. (1997): Bcl-x(L) can inhibit apoptosis in cells that have undergone Fas-induced protease activation, Proc Natl Acad Sci U S A, (Band 94), No. 8, Seite 3759-64. [136] Utz, P. J.; Hottelet, M.; Schur, P. H. und Anderson, P. (1997): Proteins phosphorylated during stress-induced apoptosis are common targets for autoantibody production in patients with systemic lupus erythematosus, J Exp Med, (Band 185), No. 5, Seite 843-54.

[137] Boise, L. H.; Gottschalk, A. R.; Quintans, J. und Thompson, C. B. (1995): Bcl-2 and Bcl-2-related proteins in apoptosis regulation, Curr Top Microbiol Immunol, (Band 200), Seite 107-21. [138] Screaton, G. R.; Xu, X. N.; Olsen, A. L.; Cowper, A. E.; Tan, R.; McMichael, A. J. und Bell, J. I. (1997): LARD: a new lymphoid-specific death domain containing receptor regulated by alternative pre-mRNA splicing, Proc Natl Acad Sci U S A, (Band 94), No. 9, Seite 4615-9. [139] Shaham, S. und Horvitz, H. R. (1996): An alternatively spliced C. elegans ced-4 RNA encodes a novel cell death inhibitor, Cell, (Band 86), No. 2, Seite 201-8. [140] Wang, L.; Miura, M.; Bergeron, L.; Zhu, H. und Yuan, J. (1994): Ich-1, an Ice/ced-3-related gene, encodes both positive and negative regulators of programmed cell death., Cell, (Band 78), Seite 739-50.